DNAJC2/MPP11 (D6B1E) Rabbit mAb #12844
- WB
- IP
- eCLIP
Supporting Data
| REACTIVITY | H M R Mk |
| SENSITIVITY | Endogenous |
| MW (kDa) | 80 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
- eCLIP-eCLIP
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
- Mk-Monkey
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
| eCLIP | 1:200 |
Storage
Protocol
Specificity / Sensitivity
DNAJC2/MPP11 (D6B1E) Rabbit mAb recognizes endogenous levels of total DNAJC2/MPP11 protein.
Species Reactivity:
Human, Mouse, Rat, Monkey
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro540 of human DNAJC2/MPP11 protein.
Background
DnaJ/Hsp40 proteins are a conserved family of J-domain-containing chaperone proteins that assist in protein folding and stability through their interactions with Hsp70 chaperone proteins (reviewed in 1). DNAJC2, also known as MPP11 (M-phase phosphoprotein 11 protein) or ZRF1, is a component of the ribosome-associated complex (RAC). The RAC is localized to the cytoplasm, where it assists in maintaining appropriate folding of nascent polypeptides by stimulating the ATPase activity of Hsp70 chaperone proteins (2,3). In the nucleus, MPP11 is involved in the activation of transcription through mediation of the switch from polycomb-repressed to active chromatin (4). Previous studies have shown MPP11 is overexpressed in leukemia and head and neck cancer, leading researchers to suggest MPP11 may be a potential therapeutic target (5-7). MPP11 is phosphorylated at serine 47 by S6 kinase, which regulates senescence in fibroblast cells (8).
- Qiu, X.B. et al. (2006) Cell Mol Life Sci 63, 2560-70.
- Hundley, H.A. et al. (2005) Science 308, 1032-4.
- Otto, H. et al. (2005) Proc Natl Acad Sci U S A 102, 10064-9.
- Richly, H. et al. (2010) Nature 468, 1124-8.
- Greiner, J. et al. (2003) Int J Cancer 106, 224-31.
- Resto, V.A. et al. (2000) Cancer Res 60, 5529-35.
- Tabarkiewicz, J. and Giannopoulos, K. (2010) Transplant Proc 42, 3293-6.
- Barilari, M. et al. (2017) EMBO J 36, 736-750.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.